[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100443184":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":18,"centralContacts":25,"locations":32,"responsibleParty":46,"collaborators":48,"id":56,"slug":10,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":10,"eligibilityCriteria":61,"healthyVolunteers":57,"sex":62,"minAge":63,"maxAge":10,"enrollmentInfo":64,"targetDuration":67,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":34,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Hannover Medical School","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TherVacB Subgroup",null,"No interventions. The participating study centers of the EU funded project \"TherVacB\" recruit patients with stricter inclusion- and exclusion criteria, hence forming a sub-cohort.",[13],"Other: No intervention",[15],{"type":6,"name":16,"description":16,"armGroupLabels":17,"otherNames":10},"No intervention",[9],[19,22],{"name":20,"affiliation":5,"role":21},"Markus Cornberg","PRINCIPAL_INVESTIGATOR",{"name":23,"affiliation":24,"role":21},"Xavier Forns","Fundacio Clinic per a la Recerca Biomedica",[26],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},"Petra Dörge","CONTACT","+49511532","6057","doerge.petra@mh-hannover.de",[33],{"facility":5,"status":34,"city":35,"state":10,"zip":36,"country":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"RECRUITING","Hanover","30625","Germany",{"type":39,"coordinates":40},"Point",[41,42],9.73322,52.37052,{"lat":42,"lon":41},[45],{"name":27,"role":28,"phone":29,"phoneExt":30,"email":31},{"type":47,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[49,51,53],{"name":50,"class":6},"European Union",{"name":52,"class":6},"German Center for Infection Research",{"name":54,"class":55},"German Liver Foundation (DLS)","UNKNOWN","100443184",false,"NCT05051098","A Non-interventional Registry for Patients with Hepatitis B Virus Infection","The European HBV Registry: a Joint Initiative of TherVacB and DZIF","Inclusion Criteria:\n\n* Hepatitis B Virus Infection\n\nTherVacB sub-cohort:\n\n* confirmed chronic hepatitis B virus infection: HBsAg positive for at least 1 year prior inclusion\n* HBeAg status documented for at least 6 months\n\nExclusion Criteria:\n\nTherVacB sub-cohort:\n\n* age \\>70 years\n* co-infection with HIV, HCV (RNA positive),\n* clinically relevant concomitant liver diseases (ALD, NASH, Haemochromatosis, Autoimmune hepatitis, AT1, Wilson's disease, primary biliary cirrhosis etc.)\n* significant comorbidities (e.g. malignancies)\n* immunosuppressive treatment (\\> 40 mg Cortisol- equivalent)\n* liver cirrhosis (judged clinically or based on ultrasound\u002Ftransient elastography)\n* History of hepatocellular carcinoma","ALL","18 Years",{"count":65,"type":66},3000,"ESTIMATED","5 Years","OBSERVATIONAL","In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials.\n\nExtensive analyses of virus and host-specific parameters are to be carried out from these patients. The knowledge gained thereby should contribute to a better understanding of the HBV control and enable patient stratification with regard to immunomodulatory therapies.\n\nFurthermore, hepatitis B patients are to be identified who are willing to participate in future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic vaccines).",[71],"Hepatitis B Virus Infection","2025-03-11",{"date":74,"type":75},"2025-03-13","ACTUAL",{"date":77,"type":75},"2021-05-06",{"date":79,"type":66},"2025-12",{"name":5,"class":6},1]